Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LXI-15028 for Non-erosive Reflux Disease (NERD) – Phase III
CTR20181521Phase 3Completed
- Sponsor
- Roxin Pharmaceutical
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tegoprazan in gastroesophageal reflux disease (GERD), sponsored by Roxin Pharmaceutical. Started Sep 2018; status: completed.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on CTR20181521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181521.